N. Fotouhi

The heme oxygenase-1 metalloporphyrin inhibitor stannsoporfin enhances the bactericidal activity of a novel regimen for multidrug-resistant tuberculosis in a murine model

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

The paper evaluates contezolid as a potential replacement for linezolid in combination with bedaquiline and pretomanid in a murine tuberculosis model, finding comparable activity and no cross-resistance.

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.